Windtree Therapeutics Soars 48.05% on Istaroxime Patent

Windtree Therapeutics' stock surged 48.05% in pre-market trading on July 3, 2025, driven by significant developments in its intellectual property portfolio.

Windtree Therapeutics recently announced the issuance of a U.S. patent for istaroxime, a potential treatment for acute heart failure. This patent, effective until 2039, strengthens the company's intellectual property position and provides a robust framework for future market exclusivity.

Acute heart failure is a critical health issue, with over 1.3 million patients hospitalized annually in the U.S. alone. Istaroxime, which has completed two positive Phase 2 studies for acute heart failure and two positive early cardiogenic shock studies, is poised to address this significant medical need.

Jed Latkin, CEO of Windtree, expressed optimism about the patent, stating that it would provide protection until 2039 if istaroxime is approved for acute heart failure. The company believes that istaroxime's unique profile, which includes improving both systolic and diastolic cardiac function, sets it apart from currently available treatments.